palivizumab
ItalyDrugs containing this active substance
-
Synagis is used to protect children at high risk of developing serious diseases caused by respiratory syncytial virus (RSV). Children at risk are those born prematurely (35 weeks or less) or those born with certain heart or lung problems.
Form: solution for injection, powder and solvent
Active substance Dosage palivizumab - ATC: J06BD01
Manufacturer: ASTRAZENECA AB